Exact Sciences, a molecular diagnostics company, has filed with the Securities and Exchange Commission a universal shelf registration statement on Form S-3 providing for the offer and sale from time to time of up to $150m of securities.
The shelf registration statement is intended to give Exact Sciences the flexibility to take advantage of financing opportunities as needed or deemed desirable in light of market or other conditions.
The securities may not be sold nor may offer to buy the securities be accepted prior to the time the shelf registration statement becomes effective.
The terms of any offering under the shelf registration statement will be determined at the time of offering. Proceeds from the sale of any securities will be used for the purposes described in a prospectus supplement filed at the time of an offering.
Exact Sciences is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer.